Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential tremor following disappointing Phase 2 results. However, the company maintains several promising ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Analysts project peak sales of $1.7 billion, although the path to reaching this figure may be gradual. Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential ...

In Wednesday’s 2024 full-year earnings, the Cambridge drugmaker gave more details on cuts to its early-stage pipeline. Biogen said it would discontinue further development of certain programs in ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

Biogen's pipeline has faced recent setbacks, including the discontinuation of SAGE-324 (BIIB124) for essential tremor following disappointing Phase 2 results. This adds to a series of recent ...

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal Vandana Singh Tue, Feb 18, 2025, 1:32 PM 2 min read ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...